|
Rivka Sherman-Gold, Ph.D., M.B.A.
President and Chief Executive Officer
Dr. Rivka Sherman-Gold joined Alydar in 2001 as President and Chief Executive Officer, bringing 17 years of experience in the biopharmaceutical industry.
Prior to joining Alydar, Dr. Sherman-Gold was at Abgenix, Inc. where she served as Director of Business Development since 1996. In that position, Dr. Sherman-Gold was a key
contributor to the business development growth of Abgenix from its start-up stage as a spin-out from Cell Genesys to a successful publicly traded billion-dollar leading biotechnology company. Dr. Sherman-Gold initiated and negotiated licensing and partnership agreements, and managed the transactions and relationships that generated significant revenues for Abgenix, with more than 15 pharmaceutical and biotechnology firms, including Pfizer, Schering-Plough, Amgen, SmithKline Beecham (now GlaxoSmithKline), Elan, Chiron, Millennium BioTherapeutics (Millennium Pharmaceuticals), and Centocor (Johnson & Johnson).
From 1993 to 1996, Dr. Sherman-Gold was Associate Director of Business Development at Athena Neurosciences, Inc. (acquired in 1996 by Elan Corporation). From 1989 to 1993, she held various positions at Axon Instruments, Inc., most recently serving as Director of Marketing and Scientific Applications.
Dr. Sherman-Gold was a recipient of the Chaim Weizmann Postdoctoral Fellowship, the National Amyotrophic Lateral Sclerosis (NALS) Postdoctoral Fellowship, and the Syntex Community Service Award for founding and serving as the first president of the Bay Area chapter of the Association for Women in Science (AWIS Palo Alto).
Dr. Sherman-Gold holds a B.Sc. with honors in chemistry and M.Sc. in physiology and biophysics from the Technion - Israel Institute of Technology in Haifa, Israel, and a Ph.D. in life sciences from the Weizmann Institute of Science in Rehovot, Israel. She was a postdoctoral fellow at Stanford University School of Medicine and earned an M.B.A. from California State University, San Jose.
|
 |
